Revenue from operations rose 10.34% year on year (YoY) to Rs 2,859 crore in the quarter ended 30 June 2024.
Profit before tax stood at Rs 656 crore in June 2024 quarter, up 23.54% from Rs 433 crore posted in same quarter last year.
Operating EBITDA stood at Rs 904 crore in Q1 FY25, registering a growth of 14% as against Rs 791 crore reported in Q1 FY24.
The company's India revenue grew by 15% YoY to Rs 1,635 crore in Q1 FY25, led by outperformance in focus therapies. As per All India Organization of Chemists & Druggists (AIOCD) secondary market data, IPM growth for the quarter was 8%. Torrent’s chronic business grew at 14% versus IPM growth of 8%, driven by strong revival in cardiac divisions and continued traction in anti-diabetes (OAD) new launches.
Torrent Pharma's Bra...
More News
|
|